<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Karine Soetaert</style></author><author><style face="normal" font="default" size="100%">Rens,C.</style></author><author><style face="normal" font="default" size="100%">Wang,X.M.</style></author><author><style face="normal" font="default" size="100%">J. De Bruyn</style></author><author><style face="normal" font="default" size="100%">M.A. Lanéelle</style></author><author><style face="normal" font="default" size="100%">Laval,F.</style></author><author><style face="normal" font="default" size="100%">Lemassu,A.</style></author><author><style face="normal" font="default" size="100%">M. Daffe</style></author><author><style face="normal" font="default" size="100%">Bifani,P.</style></author><author><style face="normal" font="default" size="100%">Fontaine,V.</style></author><author><style face="normal" font="default" size="100%">P. Lefevre</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Increased vancomycin susceptibility in mycobacteria: a new approach to identify synergistic activity against multi-drug resistant mycobacteria36969</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrob.Agents Chemother.</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">a</style></keyword><keyword><style  face="normal" font="default" size="100%">Activity</style></keyword><keyword><style  face="normal" font="default" size="100%">Agent</style></keyword><keyword><style  face="normal" font="default" size="100%">Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Antibiotic</style></keyword><keyword><style  face="normal" font="default" size="100%">antibiotics</style></keyword><keyword><style  face="normal" font="default" size="100%">approach</style></keyword><keyword><style  face="normal" font="default" size="100%">approaches</style></keyword><keyword><style  face="normal" font="default" size="100%">article</style></keyword><keyword><style  face="normal" font="default" size="100%">BCG</style></keyword><keyword><style  face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style  face="normal" font="default" size="100%">Biology</style></keyword><keyword><style  face="normal" font="default" size="100%">Brussels</style></keyword><keyword><style  face="normal" font="default" size="100%">Bruxelles</style></keyword><keyword><style  face="normal" font="default" size="100%">Clinical</style></keyword><keyword><style  face="normal" font="default" size="100%">comparing</style></keyword><keyword><style  face="normal" font="default" size="100%">de</style></keyword><keyword><style  face="normal" font="default" size="100%">disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Diseases</style></keyword><keyword><style  face="normal" font="default" size="100%">DRUG</style></keyword><keyword><style  face="normal" font="default" size="100%">electronic</style></keyword><keyword><style  face="normal" font="default" size="100%">France</style></keyword><keyword><style  face="normal" font="default" size="100%">health</style></keyword><keyword><style  face="normal" font="default" size="100%">Hygiene</style></keyword><keyword><style  face="normal" font="default" size="100%">identify</style></keyword><keyword><style  face="normal" font="default" size="100%">INFECTION</style></keyword><keyword><style  face="normal" font="default" size="100%">Infectious</style></keyword><keyword><style  face="normal" font="default" size="100%">Infectious diseases</style></keyword><keyword><style  face="normal" font="default" size="100%">Institute</style></keyword><keyword><style  face="normal" font="default" size="100%">IS</style></keyword><keyword><style  face="normal" font="default" size="100%">journal</style></keyword><keyword><style  face="normal" font="default" size="100%">Lipids</style></keyword><keyword><style  face="normal" font="default" size="100%">M</style></keyword><keyword><style  face="normal" font="default" size="100%">microbiology</style></keyword><keyword><style  face="normal" font="default" size="100%">Mycobacterium</style></keyword><keyword><style  face="normal" font="default" size="100%">Mycobacterium tuberculosis</style></keyword><keyword><style  face="normal" font="default" size="100%">observed</style></keyword><keyword><style  face="normal" font="default" size="100%">pharmacology</style></keyword><keyword><style  face="normal" font="default" size="100%">public</style></keyword><keyword><style  face="normal" font="default" size="100%">public health</style></keyword><keyword><style  face="normal" font="default" size="100%">Public-health</style></keyword><keyword><style  face="normal" font="default" size="100%">strain</style></keyword><keyword><style  face="normal" font="default" size="100%">Strategies</style></keyword><keyword><style  face="normal" font="default" size="100%">Strategy</style></keyword><keyword><style  face="normal" font="default" size="100%">study</style></keyword><keyword><style  face="normal" font="default" size="100%">Tuberculosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Universities</style></keyword><keyword><style  face="normal" font="default" size="100%">university</style></keyword><keyword><style  face="normal" font="default" size="100%">Vancomycin</style></keyword><keyword><style  face="normal" font="default" size="100%">WIV-ISP</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">0/8/2015</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">5060</style></number><volume><style face="normal" font="default" size="100%">59</style></volume><pages><style face="normal" font="default" size="100%">5057 - 5060</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Mycobacterium tuberculosis is wrapped in complex waxes, impermeable to most antibiotics. Comparing M. bovis BCG and M. tuberculosis mutants, lacking phthiocerol dimycocerosates (PDIM) and/or phenolic glycolipids, with wild-type strains, we observed that glycopeptides strongly inhibited PDIM deprived mycobacteria. Vancomycin together with a drug targeting lipids synthesis inhibited multidrug-resistant (MDR) and extensively-drug resistant (XDR) clinical isolates. Our study puts glycopeptides in the pipeline of potential anti-TB agents and might provide a new antimycobacterial drug-screening strategy</style></abstract><custom1><style face="normal" font="default" size="100%">39205</style></custom1><section><style face="normal" font="default" size="100%">5057</style></section></record></records></xml>